跳至主要内容

IND Filing

 Medicilon is the first CRO to offer preclinical animal testing service for the global pharmaceutical companies in China. We provide the IND application for the preclinical services. Medicilon is the CRO that fulfill both the China and US GLP standards. Medicilon could submit the application for both US FDA and CFDA for your new drug. Since 2004, we have successfully helped our clients to submit their new drug application to US FDA and CFDA and met the requirements of the US FDA and CFDA. We have undergone several inspections and passed all of them. Medicilon will provide an efficient, cost-effective and professional service to help our clients to achieve their goals.

Medicilon’s IND Application Service

With an insight into drug regulatory policy environment of China and the United States, Medicilon’s drug registration is able to provide CFDA IND application, USFDA IND / ANDA application services for domestic customers and CFDA IND / ANDA application service for foreign customers.
Medicilon’s drug registration group not only provides entire IND filing to our customers, but also provides the clients who only have IND filing requirements.

Medicilon’s IND Filling Services

  • Preparation and submission of CFDA IND documents for domestic customers
  • Proxy of USFDA IND/ANDA documents submission for domestic customers
  • Proxy of CFDA IND/ANDA documents submission for foreign customers
  • Project management services (only for customers with complete preclinical study)
  • Review, collation and technical evaluation of the IND / ANDA filing documents provided by the customer; and then complete the preparation, review, editing and finalization

Before the submission of the application materials, Medicilon’s IND application department will organize an internal technical communication meeting about a detailed analysis of the declaration project. After the submission of the application materials, there will be a senior reporting person in charge of the continuous communication with the regulatory body, and ensure a real-time follow-up reporting progress until the declaration of the successful completion.
In addition, according to the recent analysis of domestic drug filing data, the Chinese government will setup some innovative policies which have been evident in the drug declaration. Therefore, it is expected that the innovative drugs in China will have a good momentum of development.

Advantages of IND Application Services

  • A professional IND/ANDA research team can provide one-stop research, full project management and reporting services
  • Rich knowledge resources of CFDA/USFDA experts can provide targeted technology, regulations and reporting strategy recommendations

Medicilon’s IND application group is leading by our VP and experienced researchers, who dedicate to provide our customers a satisfactory integrated preclinical services.

Service for Complete Preclinical Study and Independent IND Application Project

(The whole set of preclinical studies include: APIs process and quality research, preparation process and quality research, efficacy, drug and safety evaluation)

  • 3 IND Packages Accepted by USFDA
  • 3 IND Packages Accepted by TGA
  • 15 IND Packages Approved by CFDA
  • 10 IND Packages Already Submitted to CFDA

Service for Complete Preclinical Study and Public IND Application Project

(The whole set of preclinical studies include: APIs process and quality research, preparation process and quality research, efficacy, drug and safety evaluation)

  • FZ016, chemical medicine category 1, planned CFDA and USFDA IND declaration, already got clinical approval of CFDA in August 2016, and will be declared USFDA.
  • X842, chemical medicine category 1, planned CFDA and EMEA and USFDA IND declaration, already submitted EMEA CTA documents in November 2016 and CFDA IND documents in January 2017, and will be declared USFDA.

In order to avoid the risk of registration, Medicilon’s IND application services customizes a practical registration strategy for customers to ensure a timely and accurate submission of the declaration data, This could help our customers to quickly complete the registration review process.


Contact Us 

Email : marketing@medicilon.com

Tel : +86 021 58591500

Website: https://www.medicilon.com

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文